Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity

Thrombosis Research

Volumn 131, Issue 6, 2013, Pages 535-539

  Nahar, Risha ^a,b   Dube, Divya ^c   Parakh, Rajiv ^d   Deb, Roumi ^b   Saxena, Renu ^a   Singh, Tej P ^c   Verma, Ishwar C ^a  

^a SIR GANGA RAM HOSPITAL   (India)

^b AMITY UNIVERSITY   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d Medanta Medicity Hospital   (India)

Author keywords

acenocoumarol; CYP2C9; N204H; sensitivity CYP2C9*57; warfarin

Indexed keywords

COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9;

AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; ARTICLE; BIOINFORMATICS; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BINDING SITE; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; ENZYME STRUCTURE; EXON; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEOMICS; X RAY CRYSTALLOGRAPHY;

ACENOCOUMAROL; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BINDING SITES; COUMARINS; FEMALE; FLURBIPROFEN; GENOTYPE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; MOLECULAR DOCKING SIMULATION; MUTATION, MISSENSE; PROTEIN BINDING; WARFARIN;

EID: 84878840359     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.03.019     Document Type: Article

References (23)

1. H. Takahashi, G.R. Wilkinson, R. Padrini, and H. Echizen CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences Clin Pharmacol Ther 75 5 2004 376 380
2. M. Ufer Comparative Pharmacokinetics of Vitamin K Antagonists Warfarin, Phenprocoumon and Acenocoumarol Clin Pharmacokinet 44 12 2005 1227 1246
3. J.O. Miners, and D.J. Birkett Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45 6 1998 525 538
4. S.M. He, Z.W. Zhou, X.T. Li, and S.F. Zhou Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development Curr Med Chem 18 5 2011 667 713
5. E. Pautas, C. Moreau, I. Gouin-Thibault, J.L. Golmard, I. Mahé, and C. Legendre Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients Clin Pharmacol Ther 87 1 2010 57 64
6. L. Bodin, C. Verstuyft, D.A. Tregouet, A. Robert, L. Dubert, and C. Funck-Brentano Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity Blood 106 1 2005 135 140
7. L.E. Visser, R.H. van Schaik, M. van Vliet, P.H. Trienekens, P.A. De Smet, and A.G. Vulto The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon Thromb Haemost 92 1 2004 61 66
8. H.G. Xie, H.C. Prasad, R.B. Kim, and C.M. Stein CYP2C9 allelic variants: ethnic distribution and functional significance Adv Drug Deliv Rev 54 2002 1257 1270
9. G.P. Aithal, C.P. Day, P.J. Kesteven, and A.K. Daly Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 9154 1999 717 719
10. D. Si, Y. Guo, Y. Zhang, L. Yang, H. Zhou, and D. Zhong Identification of a novel variant CYP2C9 allele in Chinese Pharmacogenetics 14 2004 465 469
11. G. D'Andrea, R.L. D'Ambrosio, P.D. Perna, M. Chetta, R. Santacroce, and V. Brancaccio A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 2 2005 645 649
12. S. Rozen, and H. Skaletsky Primer3 on the WWW for general users and for biologist programmers S. Krawetz, S. Misener, Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000 Humana Press Totowa, NJ 365 386
13. C.M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites J Mol Graph Model 21 2003 289 307
14. T.A. Jones, J. Zou, S.W. Cowan, and M. Kjeldgaard Improved methods for building models in electron density maps and the location of errors in these models Acta Crystallogr 47 1991 110 118
15. o resolution J Biol Chem 279 34 2004 35630 35637
16. P.A. Williams, J. Cosme, A. Ward, H.C. Angove, D. Matak Vinkovic, and H. Jhoti Crystal structure of human cytochrome P450 2C9 with bound warfarin Nature 424 2003 464 468
17. A.E. Rettie, and J.P. Jones Clinical and toxicological relevance of CYP2C0: Drug-Drug Interactions and Pharmacogenetics Annu Rev Pharmacol Toxicol 45 2005 477 494
18. V.A. Payne, Y.T. Chang, and G.H. Loew Homology Modeling and Substrate Binding Study of Human CYP2C9 Enzyme Proteins Struct Funct Genet 37 1999 176 190
19. J.M. Schwarz, C. Rödelsperger, M. Schuelke, and D. Seelow MutationTaster evaluates disease-causing potential of sequence alterations Nat Methods 7 8 2010 575 576
20. P.D. Thomas, A. Kejariwal, N. Guo, H. Mi, M.J. Campbell, and A. Muruganujan Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools Nucleic Acids Res 34 2006 645 650
21. P.C. Ng, and S. Henikoff SIFT: Predicting amino acid changes that affect protein function Nucleic Acids Res 31 13 2003 3812 3814
22. I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, and P. Bork A method and server for predicting damaging missense mutations Nat Methods 7 4 2010 248 249
23. L.E. Visser, R.H. van Schaik, M. van Vliet, P.H. Trienekens, P.A. De Smet, and A.G. Vulto Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants Clin Pharmacol Ther 77 6 2005 479 485